A
Andrew G. Nicholson
Researcher at National Institutes of Health
Publications - 512
Citations - 87875
Andrew G. Nicholson is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Lung cancer & Idiopathic pulmonary fibrosis. The author has an hindex of 113, co-authored 477 publications receiving 73860 citations. Previous affiliations of Andrew G. Nicholson include National Yang-Ming University & University College London.
Papers
More filters
Journal ArticleDOI
Challenges in pulmonary fibrosis . 4: smoking-induced diffuse interstitial lung diseases.
TL;DR: The histological, radiological and clinical features of respiratory bronchiolitis, RBILD and DIP are reviewed, with particular reference to management issues; Langerhans’ cell histiocytosis is covered elsewhere in this series of articles.
Journal ArticleDOI
Expression of muscarinic receptors by human macrophages
Akira Koarai,S L Traves,Peter Fenwick,S M Brown,Kirandeep K. Chana,Richard Russell,Andrew G. Nicholson,PJ Barnes,Louise E. Donnelly +8 more
TL;DR: Stimulation of macrophage M3 receptors promotes release of LTB4, suggesting that anti-muscarinic agents may be anti-inflammatory.
Journal ArticleDOI
Diffuse Pulmonary Ossification in Fibrosing Interstitial Lung Diseases: Prevalence and Associations
Ryoko Egashira,Joseph Jacob,Maria Kokosi,Anne-Laure Brun,Alexandra Rice,Andrew G. Nicholson,Athol U. Wells,David M. Hansell +7 more
TL;DR: In this paper, the prevalence of diffuse pulmonary ossification (DPO) in patients with fibrosing interstitial lung disease (ILD) and determine whether there are differences among the types of ILDs was investigated.
Journal ArticleDOI
Diffuse lung disease in infancy and childhood: expanding the chILD classification.
TL;DR: The aims of this study were to determine the utility and reproducibility of this classification system for DPLD in children <2 years of age, and test its extension to 18 years ofAge.
Journal ArticleDOI
The value of PE-10, a monoclonal antibody against pulmonary surfactant, in distinguishing primary and metastatic lung tumours.
TL;DR: A new monoclonal antibody raised against components of pulmonary surfactant is highly specific and moderately sensitive for primary tumours of the lung.